Thomas Rutherford
About
Thomas Rutherford is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology.
According to data from OpenAlex, Thomas Rutherford has authored 195 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Reproductive Medicine, 61 papers in Obstetrics and Gynecology and 60 papers in Oncology. Recurrent topics in Thomas Rutherford's work include Ovarian cancer diagnosis and treatment (67 papers), Endometrial and Cervical Cancer Treatments (43 papers) and Uterine Myomas and Treatments (23 papers). Thomas Rutherford is often cited by papers focused on Ovarian cancer diagnosis and treatment (67 papers), Endometrial and Cervical Cancer Treatments (43 papers) and Uterine Myomas and Treatments (23 papers). Thomas Rutherford collaborates with scholars based in United States, Italy and China. Thomas Rutherford's co-authors include Gil Mor, Peter E. Schwartz, Ayesha B. Alvero, Dan‐Arin Silasi, Masoud Azodi, Irene Visintin, Alessandro D. Santin, Peter E. Schwartz, Michael Kelly and Stefania Bellone and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Thomas Rutherford
192 papers receiving 7.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Thomas Rutherford United States | 46 | 2.9k | 2.4k | 2.3k | 1.8k | 1.4k | 195 | 7.9k | ||
| Adnan Munkarah United States | 41 | 1.9k 0.7× | 1.5k 0.6× | 2.0k 0.9× | 1.8k 1.0× | 1.1k 0.7× | 182 | 6.2k | ||
| S. Diane Yamada United States | 40 | 3.1k 1.1× | 2.2k 0.9× | 1.9k 0.8× | 1.8k 1.0× | 2.1k 1.5× | 102 | 8.0k | ||
| Masaki Mandai Japan | 49 | 2.9k 1.0× | 4.6k 1.9× | 2.8k 1.2× | 1.8k 1.0× | 1.2k 0.9× | 354 | 10.7k | ||
| Aikou Okamoto Japan | 36 | 4.4k 1.5× | 1.9k 0.8× | 1.7k 0.7× | 1.1k 0.6× | 3.1k 2.2× | 267 | 8.0k | ||
| Hal W. Hirte Canada | 45 | 3.2k 1.1× | 3.7k 1.5× | 2.3k 1.0× | 587 0.3× | 977 0.7× | 156 | 8.1k | ||
| Toshiharu Kamura Japan | 41 | 2.1k 0.7× | 1.5k 0.6× | 3.1k 1.3× | 2.8k 1.6× | 708 0.5× | 188 | 7.5k | ||
| Byoung‐Gie Kim South Korea | 45 | 1.8k 0.6× | 1.8k 0.7× | 2.6k 1.1× | 2.6k 1.5× | 1.1k 0.8× | 318 | 7.5k | ||
| Marie Plante Canada | 46 | 1.6k 0.5× | 2.4k 1.0× | 3.3k 1.4× | 3.4k 1.9× | 816 0.6× | 210 | 7.3k | ||
| Robert Zeillinger Austria | 52 | 4.7k 1.6× | 3.7k 1.5× | 1.6k 0.7× | 620 0.3× | 3.1k 2.1× | 284 | 9.3k | ||
| Claire F. Verschraegen United States | 46 | 2.0k 0.7× | 3.0k 1.2× | 1.2k 0.5× | 699 0.4× | 671 0.5× | 267 | 6.9k |
Countries citing papers authored by Thomas Rutherford
Since
Specialization
Citations
This map shows the geographic impact of Thomas Rutherford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Rutherford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Rutherford more than expected).
Fields of papers citing papers by Thomas Rutherford
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas Rutherford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Rutherford. The network helps show where Thomas Rutherford may publish in the future.
Co-authorship network of co-authors of Thomas Rutherford
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Rutherford. A scholar is included among the top collaborators of Thomas Rutherford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Rutherford. Thomas Rutherford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Guo, Xiaofang, Maja Okuka, Aslı Özmen, et al.. (2024). Spatially restricted ecto‐5′‐nucleotidase expression promotes the growth of uterine leiomyomas by modulating Akt activity. The FASEB Journal. 38(19). e70084–e70084.
2.
Alvero, Ayesha B., Rouba Ali‐Fehmi, Radhika Gogoi, et al.. (2023). Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer. Frontiers in Immunology. 14.
3.
Alvero, Ayesha B., Alexandra Fox, Bhaskara Reddy Madina, et al.. (2023). Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory. Cancer Immunology Research. 12(2). 261–274.
4.
Jessel, Shlomit, Ayesha B. Alvero, Dan‐Arin Silasi, et al.. (2021). Automated Assay of a Four-Protein Biomarker Panel for Improved Detection of Ovarian Cancer. Cancers. 13(2). 325–325.
5.
Randall, Marcus E., Virginia L. Filiaci, D. Scott McMeekin, et al.. (2019). Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer. Journal of Clinical Oncology. 37(21). 1810–1818.
6.
Piedmonte, Marion, Paul K. J. Han, Richard P. Moser, et al.. (2017). Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study. Obstetrical & Gynecological Survey. 72(6). 336–337.
7.
Schwab, Carlton L., Diana P. English, Jonathan Black, et al.. (2015). Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology. 139(1). 112–117.
8.
Coleman, Robert L., Michael W. Sill, Katherine M. Bell‐McGuinn, et al.. (2015). A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 137(3). 386–391.
9.
Rutherford, Thomas, James W. Orr, Edward C. Grendys, et al.. (2014). A Prospective Study Evaluating the Clinical Relevance of a Chemoresponse Assay for Treatment of Patients With Persistent or Recurrent Ovarian Cancer. Obstetrical & Gynecological Survey. 69(5). 259–260.
10.
Craveiro, Vinicius, Yang Yang‐Hartwich, Jennie C. Holmberg, et al.. (2013). Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Medicine. 2(6). 987–987.
11.
Yu, Herbert, Thomas Rutherford, Masoud Azodi, et al.. (2012). Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal of Surgical Oncology. 107(2). 195–200.
12.
Guzzo, Federica, Stefania Bellone, Natália Buza, et al.. (2012). HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas. International Journal of Gynecological Pathology. 31(3). 211–221.
13.
Richter, C., Emiliano Cocco, Stefania Bellone, et al.. (2010). High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. American Journal of Obstetrics and Gynecology. 203(6). 582.e1–582.e7.
14.
Richter, C., Pei Hui, Natália Buza, et al.. (2010). HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal of Clinical Pathology. 63(6). 544–547.
15.
Visintin, Irene, Ziding Feng, Gary Longton, et al.. (2008). Diagnostic Markers for Early Detection of Ovarian Cancer. Clinical Cancer Research. 14(4). 1065–1072.
16.
Alvero, Ayesha B., Wei Chen, Alan C. Sartorelli, et al.. (2006). Triapine (3-aninopyridine-2-carboxaldehyde thiosemicarbazone) Induces Apoptosis in Ovarian Cancer Cells. Journal of the Society for Gynecologic Investigation. 13(2). 145–152.
17.
Mor, Gil, Irene Visintin, Yinglei Lai, et al.. (2005). Serum protein markers for early detection of ovarian cancer. Proceedings of the National Academy of Sciences. 102(21). 7677–7682.
18.
Rutherford, Thomas, et al.. (2004). Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to ≥ second line chemotherapy. Cancer Research. 64. 1028–1028.
19.
Peng, Xiaohua, Jong-Ho Won, Thomas Rutherford, et al.. (2001). The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.. PubMed. 61(11). 4405–13.
20.
Turner, Bruce, Jonathan Knisely, Barry M. Kacinski, et al.. (1998). Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. 40(1). 77–84.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Adnan Munkarah Breakdown of academic impact, for papers by S. Diane Yamada Breakdown of academic impact, for papers by Masaki Mandai Breakdown of academic impact, for papers by Aikou Okamoto Breakdown of academic impact, for papers by Hal W. Hirte Breakdown of academic impact, for papers by Toshiharu Kamura Breakdown of academic impact, for papers by Byoung‐Gie Kim Breakdown of academic impact, for papers by Marie Plante Breakdown of academic impact, for papers by Robert Zeillinger Breakdown of academic impact, for papers by Claire F. Verschraegen